Factbox-Global drugmakers rush to boost US presence as tariff threat looms
(Reuters) -Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs. Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales. Pfizer and AstraZeneca secured multi-year tariff exemptions through …
Factbox-Global drugmakers rush to boost US presence as tariff threat looms Read More »










